10:29 AM EDT, 03/10/2025 (MT Newswires) -- Novo Nordisk's ( NVO ) US-listed stock was falling intraday Monday after the latest trial results of the Danish pharmaceutical giant's investigative weight loss drug trailed its own initial expectations.

Patients treated with the therapeutic candidate, called CagriSema, experienced a weight loss of 15.7% after 68 weeks versus 3.1% with placebo, based on results from a second phase 3 study, according to the company. The study covered 1,206 patients.

However, the print missed the drugmaker's 25% weight-loss target discussed during an earnings call in November. In December, the company announced that the product helped patients achieve a 22.7% weight loss, according to results from the first phase 3 trial.

CagriSema is a fixed-dose combination of semaglutide, which is the active ingredient in Novo's Wegovy obesity drug, and cagrilintide, an amylin analog. Shares of Novo Nordisk ( NVO ) on the New York Stock Exchange declined 8.8% in Monday trade.

The company said the latest trial achieved its primary endpoint with CagriSema demonstrating "a statistically significant and superior weight loss" versus placebo.

The study showed the product "appeared to have a safe and well-tolerated profile," with the most common adverse event being gastrointestinal, Novo Nordisk ( NVO ) said.

"The Redefine 2 results confirmed the superior efficacy of CagriSema in people with overweight or obesity and type 2 diabetes," Martin Holst Lange, executive vice president for development at Novo Nordisk ( NVO ) said in a statement. "We look forward to bringing this second pivotal trial to regulatory authorities with the aim of making this next-generation therapy available to the millions of patients in need."

Novo Nordisk ( NVO ) plans to file for regulatory approval for the drug in the first quarter of 2026.

Price: 80.11, Change: -7.07, Percent Change: -8.10